- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ICYMI: Top Highlights From ACC 2022
The American College of Cardiology’s 71st Scientific Session covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.
The American College of Cardiology’s 71st Scientific Session was held on April 2-4, 2022, in Washington, DC, with a program that covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.
Here are the key takeaways from the meeting.
New HF Definition, Stage Updates Outlined in 2022 ACC/AHA/HFSA Guidelines
A panel of experts highlighted updates to the 2022 American Heart Association (AHA)/ACC/Heart Failure Society of America (HFSA) guidelines. New additions included better management that incorporated social determinants of health and a new definition for heart failure.
Dr Raul Santos Explains the Benefits of Treating Children With FH Early
Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil, spoke on the benefits and risks of early treatment for children with familial hypercholesterolemia (FH).
SCORED: Sotagliflozin Leads to Reductions in CV Death, MI, Stroke Regardless of CVD Presence
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular (CV) programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, presented updated findings from the SCORED trial that further highlight the benefits of sotagliflozin among patients with type 2 diabetes and chronic kidney disease.
Consider the Whole Patient When Choosing Treatment, Says Dr Marc Bonaca
“We have to treat our patients, not disease states,” said Marc Bonaca, MD, MPH, CPC of Clinical Research, CPC of Community Health, University of Colorado School of Medicine, in an interview on holistic approaches and rivaroxaban treatment.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Reaching Rural America: Value-Based Care Solutions for Systemic Health and Social Inequalities
March 7th 2023On this episode of Managed Care Cast, we speak with Jennifer Schneider, MD, co-founder and chief executive officer of Homeward, a value-based care provider aiming to improve access to high-quality care in rural communities through tech-enabled clinical services, partnerships with local physicians and health plans, and community-level demographic data.
Listen
